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Abstract
Spinal epidural lipomatosis is a rare complication of chronic corticosteroid treatment. We report a new pediatric
case and an analysis of this and 19 pediatric cases identified in the international literature. The youngest of these
combined 20 patients was 5 years old when lipomatosis was diagnosed. Lipomatosis manifested after a mean of
1.3 (+/- 1.5) years (SD) (median, 0.8 years; range, 3 weeks - 6.5 years) of corticosteroid treatment. The corticosteroid
dose at the time of presentation of the lipomatosis ranged widely, between 5 and 80 mg of prednisone/day. Back
pain was the most common presenting symptom. Imaging revealed that lipomatosis almost always involved the
thoracic spine, extending into the lumbosacral region in a subset of patients. Predominantly lumbosacral
involvement was documented in only two cases. Although a neurological deficit at presentation was documented
in about half of the cases, surgical decompression was not performed in the cases reported after 1996. Instead,
reducing the corticosteroid dose (sometimes combined with dietary restriction to mobilize fat) sufficed to induce
remission. In summary, pediatric spinal epidural lipomatosis remains a potentially serious untoward effect of
corticosteroid treatment, which, if recognized in a timely manner, can have a good outcome with conservative
treatment.
Introduction
Spinal epidural lipomatosis is a rare but well documented
untoward effect of chronic corticosteroid treatment that
was first described 1975 in an adolescent treated with
corticosteroids after a kidney transplant [1]. Besides this
iatrogenic etiology, there are idiopathic cases that share
adiposity as a risk factor [2,3] and may manifest even in
the pediatric age group [4]. Independent of the cause, an
overgrowth of fatty tissue in the epidural sac leads to
back pain and symptoms of spinal nerve or cord com-
pression, depending on the location and extent of the
lesion. Diagnosis is best made by spinal magnetic reso-
nance imaging (MRI), and treatment consists of steroid
reduction, which is sometimes combined with dietary
restriction of carbohydrate or fat intake to help metabo-
lize the fat. Surgical decompression by laminectomy is
reserved for severe cases [2]. The exact pathogenic
mechanism of corticosteroid-associated epidural lipo-
matosis is unclear. Although it likely represents a sub-
type of iatrogenic Cushing syndrome, it remains to be
explained why only a small percentage of individuals
on chronic corticosteroid treatment develop an accu-
mulation of fatty tissue at this particular anatomic
site. Whereas epidural lipomatosis in adults has been
subject to relatively large studies [2], only case reports
[1,5-14] and three small series [15-17] have dealt with
this entity in the pediatric age group. We now present
an e wp e d i a t r i cc a s eo fc o r ticosteroid-associated
spinal epidural lipomatosisa n da nu p d a t e da n a l y s i so f
the pediatric cases published in the international
literature.
Patients and Methods
Case report
A 10-year-old Caucasian girl (weight, 36 kg) presented
with pain of the ear helices and pain and swelling of
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any medium, provided the original work is properly cited.several ribs bilaterally. There was a history of chronic
bilateral Achilles tendonitis and right knee arthritis. One
week later, the patient developed laryngeal pain, and
otolaryngologic evaluation revealed a partially paralyzed
vocal cord. Taken together, these findings established a
clinical diagnosis of relapsing polychondritis. The
patient was also noted to have bilateral sacroiliac (SI)
joint tenderness, and MRI revealed SI joint synovitis.
Treatment with methylprednisolone (1 g/d i.v. × 3 d),
prednisone (1 mg/kg/d), methotrexate (0.5 mg/kg s.c.
once weekly) and etanercept (25 mg s.c. once weekly)
was initiated. After one month, the prednisone was
reduced to 30 mg/day. Due to the inability to taper the
corticosteroids below 15 mg/day, etanercept was
switched to anakinra (100 mg s.c. daily) and intravenous
immunoglobulins (2 g/kg) after 3 months. Because of
persistent clinical activity and pain at the injection sites,
cytokine blockade was switched from anakinra to inflixi-
mab one month later, and methylprednisolone infusions
were resumed. At the end of this month, the patient
developed swelling and increasing pain of the lower
back. She had gained 11.5 kg, and her body mass index
(BMI) had increased from 20.7 (79
th percentile) to 23.6
(95
th percentile), respectively, by this time. In addition
to fluid along the myofascial border and persisting
bilateral sacroiliitis, an MRI of the spine and back
demonstrated marked epidural lipomatosis involving
spinal segments T1-S5 (Figure 1). Assuming that the
lipomatosis was the cause of the worsening back pain,
methylprednisolone infusions were discontinued and
prednisone was tapered from 30 mg daily to 10 mg
daily over a 4-week period. Indeed, these changes gra-
dually lead to a complete remission of the back pain
without worsening of the polychondritis. A follow up
MRI was not performed because of this dramatic
improvement. The patient remains free of back pain at
15 months of follow up.
Analysis of the literature
PubMed, Web of Science, Google Scholar and the
Chinese National Knowledge Infrastructure [CNKI
(available at http://www.cnki.net)] were searched for the
terms “lipomatosis AND [spine OR spinal OR epidural]”.
The identified reports were screened manually for
patients fulfilling inclusion criteria (corticosteroid treat-
ment, age of onset of lipomatosis before the 18
th birth-
day) and for additional reports. Sixteen cases were
identified and pooled with the 3 cases published by us
recently [17]. Together with the presented new case,
20 cases were thus available for analysis.
Results
Results of the literature analysis and the presented case
are summarized in Tables 1 and 2 and Figure 2.
The average age at diagnosis of epidural lipomatosis was
11 (+/-3.4) years (SD) (median, 11; range, 5-17) (Figure 2a).
Eleven patients (55%) were boys. Corticosteroids were
given for nephrotic syndrome in 6 cases (33%), after
organ transplantation in 4 cases (20%), for juvenile idio-
pathic arthritis in 3 cases (15%), for systemic lupus
erythematosus in 2 cases (10%), and for one case each of
Crohn disease, Sjögren syndrome, Henoch-Schönlein
purpura, pineoblastoma, and relapsing polychondritis
(presented case). Epidural lipomatosis was diagnosed
after a mean 1.3 (+/-1.5) years (SD) (median, 0.8 years;
range, 3 weeks - 6.5 years) of corticosteroid treatment.
Most cases (17/20) presented within the first 18 months
of treatment, and one case (patient 19) after only 3 weeks
(Figure 2b). Back pain was among the presenting
A
B
Figure 1 MRI including the lumbar spine, demonstrating spinal
epidural lipomatosis in the presented patient after 4.5 months
of treatment with prednisone and methylprednisolone. The
arrows point to selected areas of the pathological accumulation of
fatty tissue in the epidural space. This was not present in a baseline
MRI performed before initiation of corticosteroid therapy (image not
shown). T1 weighted images; A, sagittal plane; B, axial plane.
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was the only documented symptom in 8 patients (40%).
A neurological deficit was documented in 10 patients
(50%) at the time of diagnosis, with lower extremity
weakness being the most common one. The diagnosis
w a sm a d eb yM R Ii na l lp a t i e n t sp u b l i s h e ds i n c e1 9 9 6 .
Imaging revealed that the lipomatosis almost always
involved the thoracic spine. Lumbosacral and/or cervical
spine involvement usually resulted from extension of
lipomatosis that also involved the thoracic spine. Prefer-
ential involvement of the lumbosacral spine occurred in
only two cases (9 and 17), and isolated cervical involve-
ment was not reported. Surgical decompression was
performed in only 5 cases (25%), all of which were pub-
lished before 1997. In the other cases, reduction of cor-
ticosteroids (combined with a low-carbohydrate and/or
low-fat diet and caloric restriction in 4 cases) sufficed
to reduce lipomatosis-associated symptoms. In several
patients, corticosteroids had to be tapered despite per-
sisting activity of the underlying medical condition. In
patient 14 this was facilitated by increasing the cyclos-
porine A dose [13], in patients 16 and 17 by stepping
up disease-modifying therapy by introducing B cell
depletion with rituximab [17], in patient 19 by adding
the immunosuppressant everolimus [14], and in the pre-
sented case by switching to a different tumor necrosis
factor-a blocker. The outcome was good in all cases,
except for pt. 4 and 12 who died from progression of a
malignancy and from sepsis, respectively, shortly after
the lipomatosis was diagnosed. Patient 18 experienced
remission of the lipomatosis but died from macrophage
activation syndrome 1 year later. Importantly, perma-
nent neurological lesions were not reported in any of
the cases and did definitively not develop in patients
16-18 and 20, all of whom are known to the authors of
this report.
Table 1 Demographic and clinical characteristics of the patients
Pt. Age (years) Sex Diagnosis Duration of
steroid treat-
ment (years)
Steroid dose
(mg/d)
Therapy Clinical outcome
a Reference
1 17 (?)
b m Kidney transplant 1 40 Surgery
SR
Improvement Lee 1975 [1]
2 13 m Kidney
transplant
1.5 45 SR, diet Resolution George 1983 [5]
3 6 m JIA 4 40 Surgery
SR
Improvement Perling 1988 [6]
4 11 m Pineoblastoma 1 20 Surgery Progression of symptoms
due to spread of tumor
Quint 1988 [7]
5 6 m sJIA 1 10-40 Surgery Resolution Arroyo 1988 [8]
6 16 m Kidney
transplant
3 0.4/kg SR, diet Resolution Vazquez 1988 [9]
7 10 m NS 0.7 60 SR, diet Improvement Shirai 1990 [10]
8 11 m NS 0.8 12-60 Surgery Improvement Kano 1996 [15]
c
9 14 f NS 0.25 24-80 SR Resolution -„-
10 14 m NS 0.4 48-80 SR Resolution -„-
11 10 m HSP 0.8 36-72 SR Resolution -„-
12 8 f Crohn disease 6.5 10-60? SR Died from sepsis Muňoz 2002 [11]
13 14 m SLE 0.8 <60 SR Improvement Miller 2002 [12]
14 5 f NS 1.4 5-60 SR Resolution Kano 2004, 2005 [13,16]
15 10 f NS 0.4 20-60 SR Resolution Kano 2005 [16]
16 14 f SLE 0.5 0.2/kg SR Resolution Möller 2010 [17]
17 11 f Sjögren
syndrome
0.6 0.5/kg SR Resolution Möller 2010 [17]
18 7 f sJIA 1.5 40 SR Resolution
d Möller 2010 [17]
19 12 f Lung transplant 0.06 25 SR, diet Resolution Caruba 2010 [14]
20 10 f Relapsing
polychondritis
0.4 30 SR Resolution This report
aImprovement or resolution as interpreted from the authors’ reports of symptoms, findings or imaging.
bAge could not be determined accurately, but was more likely 17 than 18 years.
cPatient diagnosed in 1979.
dDied from chronic macrophage activation syndrome 1 year later.
Abbreviations: f, female; HSP, Henoch Schönlein purpura; LE, lower extremity; m, male; n/d, not done or not documented; NS, nephrotic syndrome; sJIA, systemic
juvenile idiopathic arthritis; SLE, systemic lupus erythematosus; SR, steroid reduction; UE, upper extremity.
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The presented case illustrates the general features of
epidural lipomatosis that were identified with the litera-
ture analysis: onset of symptoms in the context of a pro-
nounced iatrogenic Cushing syndrome –even after a
relatively short duration of corticosteroid treatment–,
back pain as the most common presenting symptom,
and a good neurological outcome without surgical inter-
vention. Therefore, new onset or worsening back pain in
a patient on chronic corticosteroid treatment should be
warning signs of epidural lipomatosis. Considering the
documented value of MRI in the early detection of epi-
dural lipomatosis [15], a spinal MRI should be per-
formed when these warning signs are present. A marked
increase in BMI, due to a corticosteroid-induced Cush-
ing syndrome, had taken place in our patient by the
time the lipomatosis manifested. In the literature analy-
sis it was not possible to calculate BMIs before initiation
of corticosteroid treatment and at the time of diagnosis
in a sufficient number of cases. However, features of a
C u s h i n gs y n d r o m ew e r ed o c u m e n t e di nm o s to ft h e
cases, thus supporting the notion that corticosteroid-
associated epidural lipomatosis represents a variant out-
come of iatrogenic Cushing syndrome. As substantiated
by the clinical improvement in our patient and by the
results of the literature analysis, reducing corticosteroid
dosing should be the first-line intervention when epi-
dural lipomatosis is detected. However, it may be
Table 2 Symptoms and neurological findings
Pt. Symptoms Documented neurological
findings
Approximate
extent
of
lipomatosis
Imaging
modality
Ref.
1 Weakness/numbness
of LE
Motor deficit LE > UE,
dysesthesia LE & front of trunk
T1-T11 Myelogram [1]
2 Hip & low back pain,
LE weakness
LE motor deficit; ankle clonus,
Babinski sign
T1-L5 Myelogram,
CT
[5]
3 LE & thorax pain; loss of function of
LE, bowel, and bladder
Paraplegia; sensory deficit below T6, poor anal sphincter tone T2-T6 Metrimazide CT
myelogram
[6]
4 LE weakness, paresthesia, bowel/
bladder dysfunction
Sensory deficit below T2-T3 T3-T9 MRI [7]
5 Back pain, paraplegia Weak tendon reflexes, sensory deficit to T6 T6-T7* CT [8]
6 Upper back and chest pain,
paraplegia
Flaccid paresis, Babinski sign, absent abdominal reflexes,
decreased LE sense of vibration
T1-T12 CT [9]
7 Back pain,
incontinence to urine,
paraplegia
LEs flaccid paresis, Babinski sign T11-L2/3* Myelogram, MRI [10]
8 Back pain, leg weakness Paraplegia T1-12* CT myelogram [15]
9 Lumbago L3-S1* MRI [15]
10 Lumbago, mid-thoracic back pain,
pain with walking
T4-8*, L4-S1* MRI [15]
11 Numbness Cutaneous sensory deficit T2-6* MRI [15]
12 Back pain,
gait disturbance
Sensory deficit to T6-T7,
UE strength 4/5, LE strength 1/5, absent knee & ankle DTRs,
Babinski sign, absent abdominal reflexes
Entire spine MRI [11]
13 Back pain Neurological exam normal T1-L3+** MRI [12]
14 Back pain T4-S1 MRI [13,16]
15 Back pain T7-T9 MRI [16]
16 Back pain, incontinence to stool and
urine, paresthesias
Increased DTRs LE,
loss of anal sphincter tone
T2- L5+** MRI [17]
17 Back pain,
radicular pain
L4-5* MRI [17]
18 Low back pain T2-S4/5 MRI [17]
19 Right LE weakness, left LE
paresthesia, dysuria
T2-T11 MRI [14]
20 Low back pain Normal neurologic exam T1-S5 MRI This
report
*Extent of cord compression.
**Lipomatosis extended caudal to L5; exact extent not documented.
Abbreviations: CT, computerized tomography; DTR; deep tendon reflex; LE, lower extremity; MRI, magnetic resonance imaging; n/d, not documented; UE, upper
extremity.
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the underlying chronic illness. As documented in
patients 12, 16, 17, 19 and 20, intensifying the disease-
modifying treatment regimen with a potentially ster-
oid-sparing agent should be considered strongly. In
addition, in patients 16 and 17 prednisone was discon-
tinued in favor of deflazacort, a corticosteroid that
may have similar immunosuppressive effectiveness as
prednisone but lower glucocorticoid side effects [18].
The role of adjunct dietary interventions geared
toward mobilizing fat deposits remains to be defined
better. In summary, epidural lipomatosis represents a
rare but potentially serious complication of chronic
corticosteroid treatment, which, if diagnosed in a
timely manner, can be treated effectively with tapering
corticosteroids.
It should be pointed out that this analysis of published
cases is subject to the well known pitfalls of publication
bias. Thus, relatively straight forward cases with a good
outcome are likely under reported and may be more com-
mon than can be gleaned from our analysis. The authors
of this report would therefore welcome input from collea-
gues around the world who are interested in formulating
larger and prospective studies relating to corticosteroid-
induced epidural lipomatosis in the pediatric age group.
Consent
Consent for publication of this report was obtained from
the patient and her parents and is available for review
by the editors of Pediatric Rheumatology.
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